Mr. Luc Tanguay reports

THERATECHNOLOGIES ANNOUNCES COMMERCIALIZATION AGREEMENT FOR EGRIFTA(TM) (TESAMORELIN FOR INJECTION) IN EUROPE

Theratechnologies Inc. has concluded an agreement with AOP Orphan Pharmaceuticals AG for the distribution and commercialization of Egrifta in several European countries.

Under the terms of the agreement, AOP will be responsible to conduct all regulatory activities to obtain marketing authorizations for Egrifta on a country-by-country basis in the territory. Prior to receiving such marketing authorizations, AOP intends to distribute Egrifta in the territory through named patient sales programs.

Theratechnologies will be responsible for the manufacture of Egrifta and its supply to AOP at a predetermined transfer price. Moreover, AOP will pay royalties on net sales of Egrifta over a certain price level. The AOP agreement further provides for a milestone payment upon obtaining marketing authorizations, pricing and reimbursement approvals in countries totalling a certain number of inhabitants, as well as milestone payments upon reaching certain levels of cumulative net sales of Egrifta in the territory. An upfront payment of 150,000 euros is associated with the execution of the agreement. Including that upfront payment, milestone payments could potentially reach a combined total of three million euros. The term of the agreement varies on a country-by-country basis and extends for seven years from the first sales of Egrifta in each country or Feb. 25, 2025, whichever is later.

"We are thrilled of our association with AOP. They have a proven track record at being successful in commercializing niche products, and this agreement gives us a great opportunity to enter the European market over a short time frame. We had set in our 2015 business plan to find a partner to distribute Egrifta in Europe. We are very pleased to have reached that objective. This is yet another significant step that aims to bring shareholder value through the realization of the full commercial potential of Egrifta," said Luc Tanguay, president and chief executive officer, Theratechnologies.

The countries covered by the distribution and licensing agreement include Austria, Albania, Belarus, Belgium, Bosnia, Bulgaria, Croatia, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Kazakhstan, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Romania, the Russian Federation, Serbia, the Slovak Republic, Slovenia, Sweden, Switzerland, Ukraine and the United Kingdom.

AOP Orphan Pharmaceuticals is a privately owned company based in Vienna, Austria. Founded in 1996, it specializes in rare diseases through the development, distribution and commercialization of innovative therapies. It currently markets 15 drugs in various European countries.

We seek Safe Harbor.